Table 1 Comparison of Takayasu arteritis (TAK) patients with and without ischemic events during the follow-up.
From: Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
All TAK patients (n = 52) | Patients with ischemic events (n = 17) | Patients without ischemic events (n = 35) | |
|---|---|---|---|
Characteristics at diagnosis | |||
Age (years) (medians; ranges) | 37.5 [16–63] | 41 [22–63] | 36 [16–62] |
Women (n; %) | 43 (83) | 12 (71) | 31 (89) |
Vascular signs | 41 (79) | 13 (76) | 28 (80) |
Fever / Weight loss (n; %) | 30 (58) | 9 (53) | 21 (60) |
C-reactive protein (mg/L) (median; range) | 43 [0–230] | 53 [1–230] | 38 [1–200] |
NIH disease activity score at diagnosis (median, range) | 3 [1–4] | 3 [1–4] | 3 [1–4] |
Cardiovascular risk factors at diagnosis | |||
Diabetes mellitus (n; %) | 1 (2) | 0 | 1 (2.9) |
Hypertension (n; %) | 19 (37) | 8 (47) | 11 (31) |
Smokers (n; %) | 16 (31) | 9 (53) | 7 (20)* |
Hyperlipidemia (n; %) | 8 (15) | 5 (29) | 3 (9) |
Body mass index | 25.8 [17.6–38] | 20.9 [17.6–29.4] | 27.1 [17.6–37.9] |
TAK treatments | |||
Glucocorticoids (n, %) at diagnosis | 40 (82) | 12/16 (75) | 28/33 (85) |
Additional immunosuppressants (n, %) at any time | 28 (62) | 11/12 (92) | 17/33 (52)* |
Biological-targeted therapies (n, %) at any time | 35 (67) | 10/15 (67) | 25/35 (71) |
Cardiovascular risk factors therapies | |||
Aspirin at diagnosis (n; %) | 33 (65) | 15 (88) | 18 (53)* |
Aspirin at any time (n; %) | 36 (69) | 15 (88) | 21 (62) |
Anticoagulants | 5 (9.6) | 3 (18) | 2 (6) |
Statins at diagnosis (n; %) | 13 (27) | 8 (47) | 5 (16)* |
Statins at any time (n; %) | 16 (32) | 8 (47) | 8 (24) |
Antihypertensive drugs at any time (n, %) | 22 (42) | 12 (71) | 10 (31)* |
ACE inhibitor at any time (n, %) | 16 (33) | 9 (53) | 7 (22)* |
β-blockers at any time (n, %) | 11 (22) | 5 (29) | 6 (19) |
Outcome | |||
Relapses | 27 (52) | 9 (53) | 18 (51) |
Follow-up (years) | 4.2 | 4.1 | 4.3 |
